Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder (Aug1)
CBT Augmentation for SRI Pharmacotherapy in OCD
研究概览
地位
条件
详细说明
Participants remain on their current OCD medication and are randomly assigned to receive one of two CBTs: exposure and ritual prevention or stress management therapy. Exposure and ritual prevention involves imaginal and in-vivo exposure and requires that participants refrain from ritualizing. Stress management involves relaxation, assertiveness training, and structured problem-solving. Therapy occurs twice per week for 2 months. Participants are assessed verbally by an independent evaluator and are asked to complete self-rating forms. Patients who respond are followed for up to 1 additional year. Participants continue to take the same medication and the same monthly therapy for the first 6 months of follow-up. During the second 6 months of follow-up, participants discontinue therapy but continue taking the same medication.
For information on a related study, please follow this link:
http://clinicaltrials.gov/show/NCT00389493
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
New York
-
New York、New York、美国、10032
- New York State Psychiactic Institute, Anxiety Disorders Clinic
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania Center for the Treatment and Study of Anxiety
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Obsessive-Compulsive Disorder (OCD) diagnosis
- Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD
Exclusion Criteria:
- Medical or psychiatric conditions that would make participation in the study hazardous
- Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Exposure and Ritual Prevention
Exposure and Ritual Prevention Therapy
|
|
|
有源比较器:Stress Management
Stress Management Therapy
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Obsessive-compulsive symptoms measured at Month 2
大体时间:2 months
|
2 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
General functioning measured at Month 2
大体时间:2 months
|
2 months
|
合作者和调查者
调查人员
- 首席研究员:Michael Liebowitz, MD、New York State Psychiatric Institute
- 首席研究员:Edna Foa, MD、University of Pennsylvania
出版物和有用的链接
一般刊物
- Farris SG, McLean CP, Van Meter PE, Simpson HB, Foa EB. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jul;74(7):685-90. doi: 10.4088/JCP.12m07789.
- Foa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill SP, Campeas R, Franklin M, Hahn CG, Hembree EA, Huppert JD, Schmidt AB, Vermes D, Williams MT. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. J Clin Psychiatry. 2013 May;74(5):464-9. doi: 10.4088/JCP.12m08017.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.